Key result
Elevated MMP-9 at presentation predicts 1-year major cardiovascular events after acute myocardial infarction.
Why the study?
Prediction of recurrent events after AMI does not sufficiently integrate systemic inflammation, coronary morphology, or ventricular function into prediction algorithms.
Do elevated systemic inflammatory biomarkers measured at presentation predict 1-year MACE in patients with revascularized acute myocardial infarction?
Cohort (n=225)
No
Do elevated systemic inflammatory biomarkers measured at presentation predict 1-year MACE in patients with revascularized acute myocardial infarction?
Answers are grounded in this paper and cite their sources.
Elevated levels of I-CAM and MMP-9 during the acute phase of myocardial infarction offer strong predictive value for 1-year MACE, outperforming left ventricular ejection fraction as prognostic markers.
(1) Background: The prediction of recurrent events after acute myocardial infarction (AMI) does not sufficiently integrate systemic inflammation, coronary morphology or ventricular function in prediction algorithms. We aimed to evaluate the accuracy of inflammatory biomarkers, in association with angiographical and echocardiographic parameters, in predicting 1-year MACE after revascularized AMI. (2) Methods: This is an extension of a biomarker sub-study of the VIP trial (NCT03606330), in which 225 AMI patients underwent analysis of systemic vulnerability and were followed for 1 year. Hs-CRP, MMP-9, IL-6, I-CAM, V-CAM and E-selectin were determined at 1 h after revascularization. The primary end-point was the 1-year MACE rate. (3) Results: The MACE rate was 24.8% (n = 56). There were no significant differences between groups in regard to IL-6, V-CAM and E-selectin. The following inflammatory markers were significantly higher in MACE patients: hs-CRP (11.1 ± 13.8 vs. 5.1 ± 4.4 mg/L, p = 0.03), I-CAM (452 ± 283 vs. 220.5 ± 104.6, p = 0.0003) and MMP-9 (2255 ± 1226 vs. 1099 ± 706.1 ng/mL p = 0.0001). The most powerful predictor for MACE was MMP-9 of >1155 ng/mL (AUC-0.786, p < 0.001) even after adjustments for diabetes, LVEF, acute phase complications and other inflammatory biomarkers. For STEMI, the most powerful predictors for MACE included I-CAM > 239.7 ng/mL, V-CAM > 877.9 ng/mL and MMP-9 > 1393 ng/mL. (4) Conclusions: High levels of I-CAM and MMP-9 were the most powerful predictors for recurrent events after AMI for the overall study population. For STEMI subjects, the most important predictors included increased levels of I-CAM, V-CAM and MMP-9, while none of the analyzed parameters had proven to be predictive. Inflammatory biomarkers assayed during the acute phase of AMI presented a more powerful predictive capacity for MACE than the LVEF.
No takes yet. Share an insight, caveat, or question.
Opincariu et al. (2021) conducted a cohort in Acute Myocardial Infarction (n=225). Elevated inflammatory biomarkers (MMP-9, I-CAM, hs-CRP) at presentation vs. Lower biomarker levels was evaluated on 1-year Major Adverse Cardiovascular Events (MACE) (AUC 0.786, p=<0.001). High levels of inflammatory biomarkers at presentation, particularly MMP-9 > 1155 ng/mL, were powerful predictors of 1-year major cardiovascular events in patients with acute myocardial infarction.
Synapse has enriched 10 related papers. Consider them for comparative context: